Anixa Biosciences (ANIX) Projected to Post Earnings on Tuesday

Anixa Biosciences (NASDAQ:ANIX) is projected to announce its Q1 2026 results before the market opens on Tuesday, March 10th. Analysts expect the company to announce earnings of ($0.09) per share for the quarter. Investors may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Friday, March 20, 2026 at 4:00 PM ET.

Anixa Biosciences (NASDAQ:ANIX) last posted its quarterly earnings data on Monday, January 12th. The company reported ($0.09) EPS for the quarter, hitting analysts’ consensus estimates of ($0.09).

Anixa Biosciences Stock Performance

NASDAQ ANIX opened at $2.85 on Monday. The stock has a 50-day simple moving average of $3.05 and a 200 day simple moving average of $3.56. Anixa Biosciences has a twelve month low of $2.33 and a twelve month high of $5.46. The stock has a market capitalization of $95.13 million, a PE ratio of -8.14 and a beta of 0.48.

Insider Buying and Selling

In other news, Director Arnold M. Baskies purchased 10,000 shares of the business’s stock in a transaction on Wednesday, January 28th. The stock was purchased at an average price of $3.04 per share, with a total value of $30,400.00. Following the acquisition, the director directly owned 135,000 shares in the company, valued at approximately $410,400. The trade was a 8.00% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. 26.40% of the stock is currently owned by company insiders.

Institutional Trading of Anixa Biosciences

A number of institutional investors and hedge funds have recently modified their holdings of the company. Bank of America Corp DE increased its position in shares of Anixa Biosciences by 1.7% during the third quarter. Bank of America Corp DE now owns 213,955 shares of the company’s stock valued at $706,000 after purchasing an additional 3,645 shares during the period. Prosperity Wealth Management Inc. lifted its position in Anixa Biosciences by 14.5% in the third quarter. Prosperity Wealth Management Inc. now owns 41,800 shares of the company’s stock worth $138,000 after purchasing an additional 5,300 shares during the period. Geode Capital Management LLC boosted its stake in Anixa Biosciences by 2.1% during the fourth quarter. Geode Capital Management LLC now owns 350,915 shares of the company’s stock worth $1,095,000 after buying an additional 7,271 shares in the last quarter. Northwestern Mutual Wealth Management Co. boosted its stake in Anixa Biosciences by 2,000.0% during the third quarter. Northwestern Mutual Wealth Management Co. now owns 10,500 shares of the company’s stock worth $35,000 after buying an additional 10,000 shares in the last quarter. Finally, NewEdge Advisors LLC bought a new stake in Anixa Biosciences in the 2nd quarter valued at $33,000. 29.13% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. D. Boral Capital reaffirmed a “buy” rating and issued a $10.00 price target on shares of Anixa Biosciences in a research report on Wednesday, February 4th. Wall Street Zen upgraded shares of Anixa Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Anixa Biosciences in a research report on Monday, December 29th. Finally, Zacks Research downgraded shares of Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 18th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Anixa Biosciences currently has an average rating of “Hold” and a consensus price target of $9.00.

About Anixa Biosciences

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.